Study Suggests Psychedelics May Help With Healing Childhood Trauma
Last reviewed and updated: June 18, 2026.
Key Takeaways
| MDMA-AT (PTSD) | 67% vs 32% no longer met PTSD criteria in MAPS Phase 3 trial — FDA rejected initial application Aug 2024; additional trials ongoing; approval ~2028–2029 |
| Psilocybin mechanism | Suppresses default mode network → increases psychological flexibility → allows reorganization of rigid trauma-frozen patterns |
| MDMA mechanism | Reduces amygdala threat response to traumatic memories while increasing empathy → allows memory processing from a regulated emotional baseline |
| vs. EMDR/CBT | Both require re-activation of traumatic memory; psychedelic therapy modifies the emotional state during processing — key advantage for treatment-resistant presentations |
| Access now | Ketamine therapy (nationwide); clinical trial enrollment (MDMA + psilocybin); Oregon psilocybin service centers |
Studies continue to show how psychedelics positively impact mental health issues. From anxiety and depression to PTSD, addiction, and even eating disorders. Now, an emerging study seems to have found a connection between these incredible hallucinogenic compounds and healing childhood trauma.
Interested in joining a Psychedelics Clinical Trial? Sign up here now and we will connect you with a clinical trial in your area when one becomes available.
What Is Childhood Trauma?
Defined as a threatening and frightening event that can severely affect and impact a child’s life, childhood trauma can come in a plethora of different types. From bullying and community violence, natural disasters and refugee trauma to medical conditions and physical or sexual abuse, there’s plenty a child can go through.
According to a study from the Substance Abuse and Mental Health Services Administration (SAMHSA), more than two-thirds of children report at least one traumatic event by the age of 16. And this number seems to only be increasing each year.
A traumatic event can potentially have massive short- and long-term negative consequences for a child. The way they react to these effects and how they learn to deal with them differs from one child to another, and furthermore, impacts the future adult they’ll become.
SAMHSA reports how “trauma is a risk factor for nearly all behavioral health and substance use disorders.” And studies show how those with childhood trauma experience adverse outcomes in adulthood including mental illness, addiction, and a variety of health problems.
Impactful and efficient treatments are important. So, too, is having a good support system — which is critical in getting a child the help they need.
RELATED: Psychedelics For Eating Disorders: An Interview With Psychiatrist And Researcher Dr. Reid Robison
Treatments For Healing Childhood Trauma
Current treatments for those suffering from some kind of childhood trauma include a mix of clinical treatments, mental health interventions, as well as other trauma-informed service approaches which are constantly improving and changing with emerging research.
Some of the most common ways for healing childhood trauma include the following.
Cognitive Processing Therapy (CPT)
This type of treatment usually comes while treating PTSD, another trauma-based mental health disorder. With children, it includes writing down the trauma memory rather than talking about it. The reasoning behind it is that writing could potentially provide some distance from the trauma itself, making the procedure more tolerable. Its most common uses are for physical and sexual abuse.
Trauma-Focused Cognitive-Behavioral Therapy
This treatment has the person create a book of the trauma memory, whether written or illustrated, in which each page of the book represents one significant part of the event. This makes it easier to break down into parts, understand the link between them, and digest each area with more success.
EMDR (Eye Movement Desensitization & Reprocessing)
A more invasive treatment, this involves having a person concentrate on the worst part of the memory while moving their eyes to follow a therapist’s moving fingers. Research shows how EDMR helps address unprocessed memories as a step for healing childhood trauma.
Narrative Exposure Therapy (NET)
This way of healing childhood trauma typically involves creating a graphic timeline of the person’s life. Along the way, a person marks all of the best and worst events from memory. It seems to be the most effective in treating people with multiple traumatic events.
Prolonged Exposure Therapy (PE)
A very gruesome treatment that has the person tell the story of the trauma memory in as much detail as possible, along with all of their thoughts and emotions. They then repeat it time and time again. Once the avoidance of the memory is prevented, the person has a chance to learn how to desensitize from it.
Play And Art Therapy
Using games and creative expression, this type of healing childhood trauma taps into the less invasive and confronting techniques. It helps those who suffered trauma to isolate those moments from their current lives. It’s usually used with children.
RELATED: I Read Every Neuroscience Study On Psychedelics Published Since 2017. Here’s What I Learned
Using Psychedelics As A Treatment For Healing Childhood Trauma
The use of psychedelics has shown to help those suffering from PTSD. So it’s no surprise researchers have interest in seeing how they may positively impact healing childhood trauma.
An article in Chronic Stress reported on the use of psychedelics in treatment as being associated with lower shame and complex trauma symptoms in adults with histories of child maltreatment.
In an online survey, 166 participants completed a series of detailed questions analyzing several factors. These included the following.
- Measures of maltreatment exposure and severity
- The history of intentional therapeutic psychedelic use
- Post-traumatic stress symptoms
- Internalized shame
- Facial emotion recognition
Of the participants, around one-third of them had tried using psychedelics (psilocybin, LSD, MDMA) in a therapeutic context in order to heal childhood trauma.
This same third reported significantly lower levels of complex trauma symptoms and feelings of internalized shame, guilt, or suicidal thoughts. This shines a new light on the use of psychedelics and their potential as an alternative treatment.
RELATED: The Stigma Of Psychedelics – Why ‘Illegal’ Doesn’t Always Mean ‘Dangerous’
What Makes Psychedelics So Effective?
One of the effects of psychedelics is ego death — the experience of losing the sense of “self”. In other words, a person loses the subjective personal identity as a temporary experience.
The majority of the participants reported feeling happier and better about themselves. They were capable of learning new steps and measures to explore unique ways to move on from past trauma.
It’s almost as if the psychedelics show them hope. A hope for changing their future. A hope for turning life into a more positive one — and not one impacted by uncontrollable events from childhood.
While the SAMHSA study is promising in the use of psychedelics for healing childhood trauma, it’s just a first step. Further research with a larger number of participants is necessary in order to confirm these findings. This could potentially move towards clinical trials. If that happens, this alternative treatment will be available to people who desperately need it.
Psychedelics are making a huge shift in the overall treatment of mental health issues. Now, childhood trauma is becoming another area where their use may be helpful. With so many studies underway, there’s no doubt we’ll be seeing a number of them in the near future.
RELATED: Heaven and Hell: Psychedelics and the ‘Gift of Trauma’
Where The Trauma Research Stands in 2025
Since this article was written, the case for psychedelic-assisted therapy in trauma-related conditions has strengthened considerably — and also encountered its first significant regulatory setback, which provides important context for where access actually stands.
MDMA-assisted therapy for PTSD. MAPS (Multidisciplinary Association for Psychedelic Studies) completed Phase 3 trials for MDMA-AT for PTSD with compelling results — approximately 67% of participants no longer met PTSD diagnostic criteria after treatment, vs. 32% in the placebo group (MAPP1 trial, NEJM 2021). However, the FDA rejected the MAPS application in August 2024, requesting additional Phase 3 data and citing methodological concerns including functional unblinding. MAPS is conducting additional trials. MDMA-AT for PTSD is not currently FDA-approved. For childhood trauma specifically, most PTSD is trauma-driven, and the MAPS data is broadly applicable — but the regulatory timeline has extended.
Psilocybin for trauma-related conditions. Johns Hopkins has published research on psilocybin’s effects on psychological flexibility, fear extinction, and trauma processing. The proposed mechanism — psilocybin’s ability to dampen default mode network activity (associated with rumination and rigid self-narrative) while simultaneously facilitating emotional processing — directly addresses the psychological mechanisms implicated in childhood trauma sequelae. NYU and Imperial College London research on psilocybin for depression and end-of-life anxiety has shown effects consistent with therapeutic trauma processing. Specific trials for childhood trauma and complex PTSD are active or in development.
Ketamine for trauma-related depression. Ketamine is currently the only psychedelic-adjacent treatment with FDA approval available for depression with potential trauma roots. Several studies have examined ketamine’s effect on PTSD symptom clusters specifically, with promising results particularly for hyperarousal and negative cognition dimensions. The rapid antisuicidal effect of ketamine — often appearing within hours — is clinically significant for the suicidality that frequently accompanies complex trauma presentations. Ketamine is available today through licensed clinics across all 50 states; this makes it the most accessible near-term option for people seeking psychedelic-adjacent trauma-informed treatment.
How Psychedelics Address Trauma Differently
Standard trauma treatments — prolonged exposure (PE), cognitive processing therapy (CPT), EMDR — require patients to repeatedly engage with traumatic memory in a relatively unmodified emotional state. Many patients find this re-exposure too activating and drop out. MDMA creates a unique state: it reduces the threat response to traumatic memories (by suppressing amygdala reactivity) while simultaneously increasing trust, empathy, and openness to insight. This allows patients to revisit traumatic material from a more regulated emotional baseline — processing the memory rather than re-traumatizing. Psilocybin’s mechanism is different but similarly aimed at disrupting the rigid, self-referential patterns that trauma entrenches: the default mode network suppression allows emotional and cognitive material to be accessed and reorganized in ways that are difficult in normal waking consciousness. Both represent genuinely different mechanisms than existing trauma treatments — which is why researchers and clinicians treating treatment-resistant trauma presentations find them compelling.
Frequently Asked Questions
Which psychedelics are being studied for childhood trauma and PTSD?
MDMA-assisted therapy has the most Phase 3 data for PTSD broadly (which includes trauma-driven PTSD from childhood experiences). MAPS’ MAPP1 trial showed 67% of MDMA-AT participants no longer met PTSD criteria after treatment vs. 32% placebo — though the FDA rejected the initial application in 2024 and additional trials are ongoing. Psilocybin is in Phase 2 trials for trauma-related conditions and depression; specific complex PTSD/childhood trauma trials are active. Ketamine is available now for depression with trauma features. Ibogaine has generated significant interest for trauma (particularly in veteran populations) but remains Schedule I in the U.S.
How do psychedelics help with trauma — what’s the mechanism?
Two distinct mechanisms, depending on the compound. MDMA reduces amygdala reactivity to traumatic memories (reducing the threat response) while increasing oxytocin and empathy — allowing patients to revisit trauma from a more regulated emotional baseline instead of re-experiencing it. This is why many people who didn’t respond to standard trauma exposure therapies respond to MDMA-AT. Psilocybin suppresses default mode network activity, which is associated with rigid self-referential thinking and the “frozen” narrative patterns trauma creates. It increases neuroplasticity and psychological flexibility, allowing emotional and cognitive material to be accessed and reorganized. Both mechanisms address the “stuck” quality of chronic trauma in ways standard talk therapy often cannot reach.
How is psychedelic therapy different from EMDR or CBT for trauma?
Standard trauma treatments (prolonged exposure, CPT, EMDR) require repeated re-engagement with traumatic memories in normal emotional states — which many patients find too activating, leading to high dropout rates. Psychedelic therapy modifies the emotional state during memory processing: MDMA creates a regulated, low-threat baseline for revisiting traumatic content; psilocybin creates psychological openness and flexibility that makes rigid trauma narratives more malleable. Neither is a standalone cure — both require significant therapeutic preparation and integration work. They are better understood as amplifiers of the therapeutic process rather than replacements for it. For treatment-resistant presentations (people who haven’t responded to multiple conventional treatments), this is the primary argument for pursuing psychedelic-assisted approaches.
How do I access psychedelic therapy for trauma right now?
Currently available legal options in the U.S.: (1) Ketamine-assisted therapy — available nationwide through licensed clinics; several ketamine providers specifically focus on trauma-informed protocols and offer integration therapy alongside infusions. (2) Clinical trial enrollment — ClinicalTrials.gov lists active and recruiting trials for MDMA-AT and psilocybin in trauma-related conditions. (3) Oregon psilocybin service centers — supervised psilocybin sessions without diagnosis requirements (note: this is not a clinical treatment protocol, but provides supervised access). For MDMA-AT specifically, the trial pathway remains the only legal U.S. access while the FDA review continues. International options (Australia for psilocybin as a prescription, retreat settings) exist but require careful vetting.
